Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Moderate Buy” by Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $36.40.

Several analysts have issued reports on RCUS shares. Truist Financial initiated coverage on Arcus Biosciences in a report on Monday, May 18th. They set a “buy” rating and a $35.00 price target for the company. Morgan Stanley lifted their price target on shares of Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Monday, May 11th. Lifesci Capital initiated coverage on Arcus Biosciences in a report on Thursday, June 4th. They set an “outperform” rating and a $46.00 price objective on the stock. The Goldman Sachs Group upped their target price on shares of Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen downgraded Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th.

Insider Buying and Selling

In related news, President Juan C. Jaen sold 20,067 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $28.62, for a total transaction of $574,317.54. Following the completion of the sale, the president directly owned 822,240 shares of the company’s stock, valued at approximately $23,532,508.80. This trade represents a 2.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,562 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $25.77, for a total value of $66,022.74. Following the sale, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at $1,020,002.37. This represents a 6.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 110,325 shares of company stock valued at $3,174,319 in the last ninety days. 7.60% of the stock is owned by company insiders.

Institutional Trading of Arcus Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Nicholas Investment Partners LP purchased a new stake in Arcus Biosciences in the 4th quarter valued at about $4,869,000. Aberdeen Group plc increased its position in shares of Arcus Biosciences by 16.0% during the fourth quarter. Aberdeen Group plc now owns 384,601 shares of the company’s stock worth $9,165,000 after acquiring an additional 52,930 shares during the period. First Turn Management LLC purchased a new position in shares of Arcus Biosciences during the fourth quarter worth approximately $13,467,000. Baker BROS. Advisors LP bought a new stake in shares of Arcus Biosciences during the fourth quarter valued at approximately $6,434,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Arcus Biosciences during the first quarter valued at approximately $1,862,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Price Performance

NYSE RCUS opened at $28.18 on Tuesday. The business’s fifty day moving average price is $27.00 and its 200-day moving average price is $24.05. The stock has a market capitalization of $3.54 billion, a price-to-earnings ratio of -8.86 and a beta of 0.80. Arcus Biosciences has a 1-year low of $8.84 and a 1-year high of $31.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The business had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.48 million. During the same period in the previous year, the company earned ($1.14) EPS. Arcus Biosciences’s revenue for the quarter was down 39.3% compared to the same quarter last year. On average, equities analysts predict that Arcus Biosciences will post -3.66 earnings per share for the current year.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.